Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-7 ل  7 نتائج ل ""Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]""

فلترة النتائج

Subject : breast neoplasms
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

Subjects: Cancer Research; SYMPTOMS; Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Fatigue [DISEASES]

  • Source: ScientiaINTERNATIONAL JOURNAL OF CANCER

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Subjects: Diarrhea; Receptor, ErbB-2; Science

  • Source: Nat CommunNature Communications, Vol 14, Iss 1, Pp 1-12 (2023)Scientia

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Subjects: Paclitaxel; Class I Phosphatidylinositol 3-Kinases; Receptor, ErbB-2

  • Source: Breast Cancer Res TreatScientia

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer

Subjects: Genome-wide association study; Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Genome-Wide Association Study [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]; Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]

  • Source: ScientiaRADIOTHERAPY AND ONCOLOGY

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial

Subjects: Receptor, ErbB-2; Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]; Breast Neoplasms

  • Source: JAMA OncolU. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G,

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Subjects: Adult; ART; BRCA

  • Source: ESMO OpenDocusalutConselleria de Salut i Consum del Govern de les Illes BalearsEsmo Openr-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Subjects: glicoles de polietileno; Polietilenglicoles; Doxorrubicina

  • Source: BMC MedDocusalutConselleria de Salut i Consum del Govern de les Illes BalearsDipòsit Digital de la UBUniversidad de BarcelonaBMC MEDICINEr-FISABIO. Repositorio

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-7 ل  7 نتائج ل ""Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]""